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Edited by Ned ManteiAbstract b-Lactoglobulin (BLG) is a major ruminant milk pro-
tein. A regulatory element, termed BLG-e1, was deﬁned in the
distal region of the ovine BLG gene promoter. This 299-bp ele-
ment lacks the established cis-regulatory sequences that aﬀect
milk-protein gene expression. Nevertheless, it alters the binding
of downstream BLG sequences to histone H4 and the sensitivity
of the histone–DNA complexes to trichostatin A treatment. In
mammary cells cultured under favorable lactogenic conditions,
BLG-e1 acts as a potent, position-independent silencer of
BLG/luciferase expression, and similarly aﬀects the promoter
activity of the mouse whey acidic protein gene. Intragenic
sequences upstream of BLG exon 2 reverse the silencing eﬀect
of BLG-e1 in vitro and in transgenic mice.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Milk-protein gene expression is subjected to complex regula-
tion which coordinates it with distinct stages in mammary
gland development. Lactogenesis is induced by polypeptide
and steroid hormones during the second term of pregnancy
and is mediated by cell–cell and cell–extracellular matrix
(ECM) interactions.
Speciﬁc trans-acting factors, such as signal transducer and
activator of transcription 5 (Stat5), glucocorticoid-responsive
element (GRE), and nuclear factor 1 (NF-1), which recognize
cis-acting DNA motifs located in close proximity to the tran-
scriptional start sites of casein, whey acidic protein (WAP)
and b-lactoglobulin (BLG) genes, have been implicated in
the regulation of milk-protein gene expression at speciﬁc devel-
opmental stages. Their combined action also confers mam-
mary speciﬁcity [1]. Much less is known about the location
and function of regulatory elements in the distal regions of
milk-protein gene promoters. Distal regulatory elements haveAbbreviations: BLG, b-lactoglobulin; BLG-e1, b-lactoglobulin element
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doi:10.1016/j.febslet.2005.02.061been reported for mouse WAP [2], rabbit aS1 casein [3], hu-
man b-casein [4] and bovine b-casein [5,6] genes. Their regula-
tory mechanism has not been fully identiﬁed, but appears to
require the activation of one or more of the recognized enhanc-
ers, located near the transcription-initiation sites. A possible
epigenetic eﬀect has been proposed for the BCE-1 element in
the bovine b-casein distal promoter, assuming modulation of
histone acetylation in mediating the ECM response [6]. Acety-
lation of lysine residues in the N-terminal tail of histones H3
and H4 reduces their positive charge and weakens their aﬃnity
to DNA, which, in turn, facilitates transcription-factor binding
[7].
Whereas caseins are the major milk proteins, BLG could be
considered the most characteristic of ruminants, due to its ab-
sence from human and murine milk and its highest level in
ruminant whey [8]. The ovine BLG gene has been cloned, se-
quenced and expressed at high levels in the mammary gland
of transgenic mice [9–11]. Three major DNase-1 hypersensitive
sites have been identiﬁed in the promoter region between
1800 and +100 bp from the transcription-initiation site. An
additional, less characterized site has been located at
2500 bp [10,12]. Although hypersensitive sites usually indi-
cate the presence of cis-regulatory elements, only the 400-bp
proximal region of the BLG promoter has been studied in de-
tail [12–14].
Here, we identiﬁed and studied the function of b-lactoglob-
ulin element 1 (BLG-e1), a unique regulatory element located
in the distal region of the BLG promoter, in CID-9 mammary
cells cultured under favorable lactogenic conditions and in
transgenic mice. We report that BLG-e1 aﬀects acetylation
of histone H4 and its binding to downstream BLG promoter
sequences. Depending on the presence or absence of intragenic
sequences upstream of exon 2, BLG-e1 serves as either an
essential element or a silencer of BLG promoter activity.2. Materials and methods
2.1. Construction of recombinant BLG/luciferase genes
BLG/luciferase hybrid gene constructs were prepared to study the
activity of the BLG regulatory sequences. The ﬁrst set of hybrid genes
(Fig. 1) was based on vector p904 [15–17]. In the course of its construc-
tion, BLG sequences between the ﬁrst part of exon 2 and the middle of
exon 6 (including the TAG termination codon) were deleted and re-
placed with the luciferase gene, followed by the SV40 polyadenylation
(PA) region, both from the pGL2-basic commercial vector (Promega,
Madison, WI). To avoid biphasic expression, the natural BLG ATG
translation-initiation codon as well as the second potential initiation
codon in BLG exon 1 were converted into non-initiating ATT and
ATC sequences, respectively. The resulting p904 vector is composed,blished by Elsevier B.V. All rights reserved.
Fig. 1. Silencing of BLG/luciferase gene expression by a distal region in the BLG promoter depends on intragenic sequences residing near the
transcription start site. Representation of BLG/luciferase vectors used to stably transfect CID-9 cells, and their relative activities. Luciferase cDNA
was inserted in the ﬁrst exon of the BLG gene (p915, p919, p926 and p924) or in the second exon of the BLG gene (p904 and p920). All constructs are
terminated with BLG 3 0-ﬂanking sequences.
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and a small part of exon 2. The luciferase reporter is inserted into
BLG exon 2 and followed by part of BLG exon 6/intron 6 and 1 kb
of the BLG 3 0 ﬂanking region (including the BLG PA site). The TATA
box in the BLG promoter of this construct remains 889 bp upstream of
the translation-initiation site.
To construct vector p920, p904 was shortened by 935 bp upstream of
the PvuII site. In vector p915, the pGL2 reporter was introduced into
an artiﬁcial XhoI site generated in BLG exon 1 of construct p904,
40 bp downstream of the BLG TATA box. This manipulation resulted
in the elimination of a 767-bp SnaBI–XhoI fragment containing se-
quences of BLG exon1/intron 1 and a small part of exon 2. To con-
struct vector p919, p915 was shortened by 935 bp, as in the
construction of p920. In vector p926, a distal 618-bp fragment from
the BLG promoter of p915 was excised upstream of the NsiI site. Vec-
tor p924 is a modiﬁcation of p915, lacking a 500-bp PvuII–PvuII frag-
ment downstream of position 2187 in the BLG promoter.
Vector p908 was the basis for the second set of BLG/luciferase vec-
tors (Fig. 2). It is composed of only two components: 3122 bp of the
BLG 5 0 sequence and the luciferase/SV40 reporter gene. It is much
shorter than p904, due to the absence of both the BLG exon1/intron
1/exon 2 fragment and the BLG 3 0 ﬂanking region. Here, the lucifer-
ase/SV40 reporter was linked to the BLG promoter at the XhoI site
as described above for p915. To construct vector p925, a distal 935-
bp fragment, downstream of the PvuII site in p908, was excised. In vec-
tor p927, a 500-bp PvuII–PvuII fragment was excised from the BLG
promoter of p908, as with the construction of p924. Vector p928 lacks
a BLG 5 0 distal fragment of 618 bp downstream of the NsiI site in
p908. Vector p929 results from the elongation of p925 by 254 bp down-
stream of the PvuII site. This was performed in two steps. First, a 291-
bp PCR product encompassing an artiﬁcial NheI site at its 5 0 end was
engineered, using p908 as the template and the following primers:
NheI
2439 5 0 AAG CAG CAT GGC ATg CTA GcG TGT G 3 0
2148 5 0 GAG AGA GAC GGA AAT AAA GCA GC 3 0
(positions of the primers in the BLG gene, Accession No. X68105, are
indicated. Lowercase letters designate modiﬁed nucleotides used to
engineer the restriction site). Second, the PCR product was digested
with NheI and PvuII, and the resulting 254-bp fragment was ligatedupstream of the PvuII site in the BLG promoter of p925. To generate
vector p934, a 134-bp PCR product was ampliﬁed from the BLG pro-
moter region immediately upstream of p928. With the following prim-
ers and p908 as a template, this product was engineered to contain an
artiﬁcial MluI site at its 5 0 end and NheI site at its 3 0 end.
MluI
2622 5 0 TTC ATT ACg cGT AAC TGG TCT GTT C 3 0
NheI
2489 5 0 TGC TGT GTG CTa gCA TGC ATG TCC 3 0
After digestion with these enzymes, the resultant 118-bp fragment
was ligated to the NheI site of p929. To generate vector p933, a 137-
bp PCR product ampliﬁed from a region immediately upstream of
the 5 0 end of p934 and containing the same pair of artiﬁcial sites,MluI
at its 5 0 end and NheI at its 3 0 end, was prepared, using the following
primers and p908 as a template:
MluI
2733 5 0 GCA GGG AAG ACg Cgt CAC AAC CGG 3 0
NheI
2596 5 0 TAT GAA CAG ACC AGc Tag CAG TAA TG 3 0
After digestion with the appropriate enzymes, the resultant fragment
encompassing 111 bp was ligated to the NheI site of vector p929. To
construct vector p930, the most distal SalI–BbsI 405-bp fragment of
the available BLG promoter was ligated to p929. To construct vector
p931, a 320-bp PCR product encompassing the absent region of the
BLG promoter in p930 (the predicted regulatory element) and contain-
ing artiﬁcial MluI and NheI sites was prepared using the following
primers and p908 as a template.
MluI
2733 5 0 GCA GGG AAG ACg CgtCAC AAC CGG 3 0
NheI
2413 5 0 CAC ACA CgC TAG cAT GCC ATG CTG C 3 0
The PCR fragment was digested with these enzymes and the resul-
tant 299-bp fragment was ligated to the NheI site at the 5 0 end of
p925.
Vector p932 (Fig. 3) was constructed to generate transgenic mice. A
distal 1307-bp PvuII–KpnI fragment was excised from p920 and re-
placed with the 1922-bp SalI–KpnI fragment from the promoter of vec-
tor p930. The resultant vector lacks the 299-bp predicted regulatory
element upstream of the artiﬁcial NheI site at position 2419.
Fig. 2. BLG-e1 resides within the distal region of the BLG promoter and silences BLG and WAP promoter activity when these promoters are
directly linked to the luciferase cDNA. Schematic representation of transfected BLG/luciferase and WAP/luciferase vectors used to identify BLG-e1,
and their relative activities.
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A plasmid containing the WAP promoter in the pBLCAT2 vector
was a kind gift from L. Hennighausen (NIH, Bethesda, MD). A
2177-bp EcoRI–KpnI fragment containing the WAP promoter se-
quences immediately upstream of the transcription-initiation site
was released to replace the BLG promoter in p929. This manipula-
tion resulted in the WAP/luciferase vector, p935. To generate vector
p936, a 299-bp MluI–NheI fragment (2723 to 2424, the predicted
regulatory element) from p931 was linked to the 5 0 end of p935
(Fig. 2).
2.3. Generation of BLG/luciferase transgenic mice
Mice used in this study were of the FBV/N strain. Plasmids contain-
ing BLG/luciferase sequences were restricted with SalI and the appro-
priate fragments were prepared and microinjected as describedpreviously [11]. Transgenic animals were identiﬁed by Southern blot
analysis of genomic DNA prepared from tail biopsies using a PCR
probe encompassing 417 bp of the luciferase cDNA in the pGL2-basic
vector [17].
2.4. CID-9 cell culture and transfections
CID-9 cells, an enriched population of the COMMA-1D mouse
mammary epithelial cell line [18], were grown in DMEM:F12 (1:1 Gib-
co-BRL, Paisely, UK) containing 5% fetal calf serum (FCS), gentami-
cin (50 lg/ml) and insulin (5 lg/ml). For ECM-dependent activation,
cells were plated on Matrigel (Collaborative Bio-Medical Products,
Bedford, MA) in a 24-well dish (0.3 · 106 cells/plate). DMEM:F12
containing 2% FCS, insulin (5 lg/ml), hydrocortisone (3 lg/ml) and
prolactin (3 lg/ml) was added for 24 h. The medium was then switched
to one without FCS. Transfections of BLG/luciferase gene constructs
Fig. 3. BLG-e1 is essential for in vitro and in vivo BLG promoter
activity in vectors containing intragenic sequences. BLG/luciferase
constructs with or without the BLG-e1 sequence were stably transfec-
ted into CID-9 cells and luciferase activity was determined in
diﬀerentiated, hormonally treated cells. Transgenic mice carrying these
constructs were also generated and luciferase activity was determined
in females mammary glands on day 6 of their ﬁrst lactation. Highest
and averaged activities are presented due to the heterogeneity in BLG/
luciferase expression among mammary glands [17].
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(Gibco-BRL), and selection was performed with G418 as previously
described [19].
2.5. Luciferase assay
Luciferase activity in transfected CID-9 cells and in the mammary
glands of transgenic animals was determined using the Luciferase As-
say System Kit (Promega) according to the manufacturers protocol, as
previously described [16]. The data represent means ± S.E.M. of at
least three independent analyses performed in quadruplicate. The in
vivo results represent means ± S.E.M. from at least three animals per
line.
2.6. Chromatin immunoprecipitation
Cells cultured on Matrigel were ﬁxed with 1% formaldehyde for 10
min at 37 C and chromatin immunoprecipitation was performed
using the Chromatin Immunoprecipitation Assay Kit (Upstate, Lake
Placid, NY) according to the manufacturers protocol. Brieﬂy, cells
were washed, collected and sonicated on ice in 200 ll SDS lysis buf-
fer. DNA was sheared to lengths of between 200 and 1000 bp using a
W375 sonicator (Ultrasonics Inc., Farmingdale, NY) and chromatin
immunoprecipitation was performed with anti-acetyl histone H4
polyclonal antibodies (Upstate) diluted 1:200 as described [19].
DNA–protein crosslinking was reversed by incubation at 65 C for
4 h in the presence of 20 mM NaCl. DNA was recovered by phe-
nol/chloroform extraction and PCR was performed with primers cov-
ering four 245- to 246-bp regions of the BLG promoter and a 246-bpregion of the mouse b-casein promoter, 1124 bp upstream of the
TATA box. The primers used to amplify region I of the BLG pro-
moter were:
2719 5 0 CAC AAC CGG AAA AAG GAG TTT GG 3 0
2474 5 0 AGT CTT GCT GGT CGA TGC TGT GT 3 0
The primers used to amplify region II of the BLG promoter were:
2298 5 0 ACG GGG AGA TGC TGA GAG C 3 0
2052 5 0 CCA AGT TCC TGT GAA CCG TGA C 3 0
The primers used to amplify region III of the BLG promoter were:
1348 5 0 CCC CCT GAA CTG TAG GGT CTT T 3 0
1103 5 0 CAG ATC AGG GCA AGG ACT GAA G 3 0
The primers for region IV of the BLG promoter were:
430 5 0 GTC ACA TGG TTT GGA GGA GCT G 3 0
184 5 0 ATA GGA GGC CTT CTT CCA TCC A 3 0
The primers amplifying the distal region of the b-casein promoter
were:
1498 5 0 GGG CCT AGC AAA CAC AGA AAT G 3 0
1153 5 0 GGG GCA TAT AAA GTT TGC CTG A 3 0
Ampliﬁed DNA sequences were analyzed on 1% agarose gels, blot-
ted onto membranes, reacted with 32PdATP labeled probes composed
of the relevant sequences and exposed to XAR-Kodak ﬁlm.3. Results
3.1. Deﬁning the BLG-e1 regulatory element
To locate distal regulatory elements involved in the control
of BLG expression upon lactation, BLG/luciferase hybrid
genes were constructed and stably transfected into growing
CID-9 cells. Luciferase activity was monitored in diﬀerentiated
cells cultured on Matrigel in serum-free medium and supple-
mented with insulin, hydrocortisone and prolactin.
Vector p904 contains the full set of control regions, posi-
tioned at both the 5 0 and 3 0 ends of the native BLG gene
(Fig. 1). The 5 0 region of p904 is composed of a 3.1-kb BLG
promoter sequence, followed by intragenic sequences upstream
of BLG exon 2 where the luciferase reporter is inserted. The 3 0
sequences include BLG exon 6/intron 6 and exon 7. Trunca-
tion of the distal 935 bp from the promoter of p904 (p920) re-
sulted in a 60% decrease in BLG/luciferase expression.
Vector p915, which lacks the BLG intragenic sequences near
the transcription-initiation site, retained about 60% activity
relative to p904. Surprisingly, elimination of a similar 5 0 region
from this vector (p919) restored BLG/luciferase expression to
the level induced by the full-length p904. Because it had the
shortest promoter, p919 served as a reference for the expres-
sion of all constructs containing BLG 3 0 ﬂanking sequences.
To locate putative regulatory sequences in the distal BLG
promoter, p919 was elongated by 317 bp towards its 5 0 end,
resulting in vector p926. However, this manipulation did not
aﬀect BLG/luciferase expression. In contrast, excision of a
500-bp fragment downstream of the PvuII site at position
2687, while preserving the most distal 5 0 end of the BLG pro-
moter, resulted in a doubling of BLG/luciferase expression
(p924 vs. p915).
BLG intragenic sequences at the 3 0 end of the gene can
interact with elements in the promoter region and aﬀect its
activity [15,20]. To determine the net eﬀect of the distal por-
tion of the BLG promoter, a second set of constructs was pre-
pared based on hybrid vectors devoid of BLG intragenic
sequences (Fig. 2).
Vector p908 is composed of the 3.1-kb promoter sequence
linked to luciferase cDNA. Elimination of 935 bp from its
distal end (p925) resulted in a dramatic 12-fold increase in
BLG/luciferase expression in the transfected CID-9 cells.
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the BLG promoter has also been established in an L-1 cell
line derived from bovine mammary gland [21]. Vector p925
was the shortest in the second set of constructs and served
as a reference for BLG/luciferase expression measurements
in this set. Its expression was 1.6-fold more potent than that
of p919, a homologous vector containing the BLG 3 0 se-
quences (Fig. 1).
Removal of a speciﬁc 500-bp region between the two PvuII
sites at positions 2687 and 2187 (p927) induced BLG/luciferase
expression relative to the full-length p908. However, p927 re-
mained ﬁve times less competent than the shortest p925 vector.
These results suggested that some negative regulatory ele-
ment(s) residing within the region of 2187 to 2687 might
have been removed together with sequences essential for pro-
moter activity.
In search of the regulatory elements, the 2-kb BLG pro-
moter in p925 was elongated by an additional 235 bp upstream
of its PvuII site. The resultant vector, p929, was as potent as its
shorter counterpart, suggesting that the putative regulatory re-
gion lies upstream of the 5 0 end of p929. Thus, a 299-bp frag-
ment was removed from the 3-kb BLG promoter, 5 0 to the
artiﬁcial NheI site at position 2419. The resultant vector,
p930, displayed the highest luciferase activity, double that of
p925 and over 26-fold that of the complete BLG promoter
(p908).
To identify regulatory elements residing within the excised
299-bp region, it was divided into three comparably sized
parts. Fragments of the proximal, middle and distal regions
were linked to the 5 0 end of the promoter of p929 to form vec-
tors p928, p934 and p933, respectively. Analysis of CID-9 cells
stably transfected with these three vectors indicated that
restoring each of the three parts of the excised element to
p929 decreases luciferase activity. The proximal and distal re-
gions were equally potent, inhibiting 60–70% of its activity,
whereas the middle part, included in vector p934, exerted a les-
ser inhibitory eﬀect. Finally, linking the complete 299-bp ele-
ment to the 2.1-kb promoter of the control vector p925
resulted in over 85% inhibition of BLG promoter activity.Fig. 4. Alignment of BLG-e1 sequences from the ovine BLG promoter with
corresponds to GenBank Accession No. X68105 with slight corrections we m
Z48305. Predicted binding sites for HNF-3b and TEF-1 are underlined.These results established a silencing role for this distal regula-
tory element, designated BLG-e1.
3.2. BLG-e1 inhibits WAP-directed luciferase expression
A non-speciﬁc inhibitory role for BLG-e1 was established by
its linkage to the WAP promoter (Fig. 2). Vector p935, encom-
passing 2.1 kb of the WAP promoter sequences linked to the
luciferase reporter, was constructed, and BLG-e1 was ap-
pended to its 5 0 end (p936). Comparative analysis of the po-
tency of these two vectors in directing lactogenic-induced
luciferase activity in stably transfected CID-9 cells demon-
strated an intense inhibitory eﬀect (over 90%) of BLG-e1 on
WAP promoter activity.
3.3. BLG-e1 is essential for BLG promoter activity in transgenic
mice carrying BLG/luciferase constructs containing
intragenic elements
Intragenic BLG sequences in vector p904 are essential for
its in vivo expression in mammary glands [15,16]. In the pres-
ence of these elements, the distal 5 0 region of the BLG pro-
moter contributes to expression in CID-9 cells (p920 vs.
p904). The contribution of BLG-e1 to the expression of
BLG/luciferase vectors containing intragenic elements was
studied by comparing BLG/luciferase expression directed by
p904 to that directed by p932 lacking the BLG-e1 element
(Fig. 3). In stably transfected CID-9 cells, the absence of
BLG-e1 from the BLG promoter resulted in a signiﬁcant de-
crease in BLG/luciferase expression. Four lines of transgenic
mice with stable integration of vector p932 into their genome
were generated in an attempt to study the role of BLG-e1 in
vivo. BLG/luciferase expression in their mammary glands
was compared to that in three lines of transgenic mice carry-
ing p904, representing the expresser-half of the original
cohort [16]. Two out of the four lines of mice carrying
p932 expressed detectable levels of BLG/luciferase in their
mammary glands. However levels of expression were two or-
ders of magnitude lower than those determined in p904
transgenic mice, for both the highest and average activities
in the glands.a homologous region from the bovine BLG gene. The ovine sequence
ade in AY515301. The bovine sequence corresponds to Accession No.
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Fig. 4 demonstrates 87% homology between ovine BLG-e1
and the sequence from Bos taurus – the only other available
distal BLG promoter in GenBank. A BLAST/FASTA com-
parison of BLG-e1 with sequences of all milk-protein genes
did not reveal any signiﬁcant similarities. Indeed, about 64%
similarity was found between BLG-e1 and a 192-bp fragment
of the primate consensus ancient repetitive element Lime_-
ORF2. However, at least four other sequences from the
BLG promoter, altogether representing 15% of its size, shared
similarity to Lime_ORF2. Other sequences with 75–85% simi-
larity to 90- to190-bp fragments of BLG-e1 were randomly lo-
cated in cattle, pig, cat, dog, horse, olive, baboon and human,
but not rodent, genomes.
cis-Regulatory binding sites for hepatocyte nuclear factor
(HNF) 3 and transcription enhancer factor (TEF)-1 can be
predicted with high conﬁdence within BLG-e1. However, these
transcription factors have no reported relevance to milk-pro-
tein gene expression.Fig. 5. Chromatin immunoprecipitation assay for histone acetylation
demonstrates BLG-e1s eﬀect on downstream promoter–histone com-
plexes and their sensitivity to TSA treatment. (A) Binding of diﬀerent
regions from the BLG promoter to acetylated histone H4 was examined
as described in Section 2. (B) The amount of bound DNA was
determined and compared for cells transfected by vectors p908 and
p930 after normalization to the intensity of the signal obtained by
amplifying an arbitrary region of the b-casein promoter. (C) The eﬀect
of TSA (10 lg/ml) on the binding of distinct regions from the BLG
promoter to acetylated histone H4 is BLG-e1-dependent. Levels of
bound DNA were determined in untreated cells and those treated with
TSA after normalization to the respective b-casein signal, and
compared to cells transfected with the same vector. Chromatin
immunoprecipitation was performed in duplicate. Signals obtained
from eight independent PCRs performed for each region were
quantitated after hybridization to the relevant probes and presented
as means + S.E.M. Students t test was performed to compare histone
binding to promoter regions in vectors p908 and p930. Signiﬁcant
diﬀerences of P < 0.05 or P < 0.01 are marked by one or two asterisks,
respectively.3.5. BLG-e1 alters DNA binding to acetylated histone H4
In the absence of a speciﬁc cis-regulatory candidate
sequence responsible for the BLG-e1 silencing eﬀect, we set
out to determine putative epigenetic modiﬁcations exerted
by this element. Acetylation can modulate DNA accessibility
within chromatin [22]. Furthermore, histone acetylases and
deacetylases can be recruited to speciﬁc promoters where-
upon they serve as transcription regulators [23,24]. Thus,
the eﬀect of BLG-e1 on the binding of downstream pro-
moter sequences to acetylated histone H4 was studied using
the chromatin immunoprecipitation assay. Four regions,
each covering approximately 250 bp of the distal, middle
and proximal parts of the promoter, were selected for anal-
ysis (Fig. 5A), and the amounts of sheared DNA complexed
with acetylated histone H4 were quantitated by immunopre-
cipitation and PCR ampliﬁcation of the recovered DNA.
Signiﬁcantly better binding of the distal (II) and middle
(III) regions of the BLG promoter to acetylated histone
H4 was observed in the presence of BLG-e1, whereas no ef-
fect of this element was observed for the proximal region
(IV) (Fig. 5B). Trichostatin A (TSA) inhibits histone deacet-
ylases targeted by speciﬁc DNA-binding factors to transcrip-
tionally silent mammalian genes. At a concentration of
10 lg/ml, it exhibited an optimal eﬀect on the BLG pro-
moter by inducing its activity 2.5-fold over controls (not
shown). Exposure of CID-9 cells to TSA for 18 h resulted
in a reduced level of DNA–histone complexes in all tested
regions of the BLG promoter (Fig. 5C). The absence of
BLG-e1 in vector p930 enhanced the sensitivity of histone–
promoter complexes to TSA treatment in these regions.
Thus, 1.6- to 5-fold more DNA was released from the
complex in TSA-treated cells transfected with vector p930
vs. p908. Since histone acetylation usually correlates nega-
tively with promoter binding, this complements data pre-
sented in Fig. 5B, indicating the lower acetylated status of
histones bound to regions II and III in the absence of
BLG-e1.
Not all regions of the BLG promoter were equally suscepti-
ble to TSA: less aﬀected were ‘‘I’’ within the BLG-e1 and ‘‘IV’’
near the transcription-initiation site. Interestingly, only 175 bp
separate the less aﬀected region ‘‘I’’ in the BLG-e1 site and themost aﬀected region ‘‘II’’ from which only marginal levels of
DNA were still complexed with the histone core after TSA
treatment.
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In this study, we deﬁne a distal cis-regulatory sequence in the
ovine BLG promoter at positions 2717 to 2419. This ele-
ment was termed BLG-e1. Its localization and the analysis of
its eﬀects were primarily performed in vitro, in diﬀerentiated
epithelial cells cultured under hormonal conditions favoring
milk-protein gene expression.
BLG-e1s silencing eﬀect on BLG promoter activity was
demonstrated with a basic BLG/luciferase hybrid gene consist-
ing of the 3.1-kb BLG promoter sequences linked to luciferase
cDNA [15]. Excision of BLG-e1 from this promoter resulted in
26-fold higher BLG/luciferase activity, indicating that the gene
silencing exerted by this region overcame the positive contribu-
tion of putative essential elements residing in its vicinity [13].
Consequently, a much shorter 2.1-kb promoter (p925) lacking
this region was still 12 times more potent in directing luciferase
expression than its 3.1-kb-long counterpart. Positioning BLG-
e1 adjacent to the 5 0 end of the 2.1-kb BLG promoter restored
its silencing eﬀect. Moreover, this eﬀect could also be further
extended to a WAP promoter of comparable size. Thus, a
cross-species, position-independent inhibitory eﬀect was dem-
onstrated for BLG-e1 on promoter activity.
The silencing eﬀect of BLG-e1 on BLG promoter activity
could not be established and studied in vivo since it was re-
versed by intragenic sequences upstream of exon 2. The pres-
ence of the ﬁrst intron is essential for BLG-driven cDNA
expression in transgenic mice [15,16]. Nevertheless, the diﬀer-
entiated, hormonally treated CID-9 cell system faithfully mir-
rored the contribution of BLG-e1 to BLG promoter activity in
transgenic animals carrying a hybrid construct containing
BLG intragenic sequences. Intronic sequences, especially those
next to the promoter region, contain putative and conﬁrmed
intragenic regulatory elements [25,26]. Here, we present a un-
ique case in which these sequences are not only essential for
expression, but they can also reverse the silencing eﬀect of a
distal element residing 2.4 kb upstream of the transcription-ini-
tiation site.
BLG-e1 is located in a distinct position within the BLG
promoter. It separates the genomic sequences of the ancient
repetitive element Lime_ORF2 from downstream sequences
of the BLG promoter. The similarities between BLG-e1 and
Lime_ORF2 sequences which were noted by in silico analyses
appeared to be biologically insigniﬁcant, reﬂecting ancestral
insertions [27] during the phylogenic development of the
BLG gene, which, as noted, is absent from the rodent genome.
The two predicted transcription factors for which cis-regula-
tory binding sites were determined with high conﬁdence within
BLG-e1 have no previously reported relevance to milk-protein
gene expression. HNF 3b is an important component of the
diﬀerentiation process that culminates in a fully functional li-
ver. HNF 3b knockout results in a lethal embryonic state with
failure to form endoderm or notochord [28]. TEF-1 functions
during growth by binding muscle regulatory elements [29], and
members of the TEF-1 family are required for high levels of
gene expression in skeletal and cardiac muscle [30]. No binding
sites for transcription factors known to regulate milk-protein
expression, such as the enhancers Stat5, NF-1, GRE, C/EBP
and the repressor YY1 [1], were found within BLG-e1.
The absence of deﬁned cis-regulatory sequences within
BLG-e1 with conﬁrmed relevance to BLG promoter activity
suggests that epigenetic and structural modiﬁcations are in-volved in its intragenic-dependent eﬀect. Acetylation of lysine
residues on the amino-terminal tails of the histones neutralizes
the tails positive charge and decreases their aﬃnity for DNA
[31]. Hyperacetylation has been shown to initiate loss of con-
tact with the activated gene promoter [32].
BLG-e1s interaction with histone H4 was 10-fold less af-
fected by hyperacetylation than the adjacent downstream
sequence. Nevertheless, the higher amount of DNA bound
to histone H4 in the proximal and middle regions of the
BLG-e1-devoid promoter compared to its intact counterpart
suggests that this element is involved in recruiting histone acet-
ylases which weaken promoter–histone binding. Under the
permissive conditions established by intragenic sequences of
the BLG gene, this could favor gene transcription. Thus,
although BLG-e1-dependent promoter acetylation has been
shown in the absence of intragenic sequences, it most probably
occurs also in their presence.
Intragenic sequences have already been shown to aﬀect the
promoters chromatin [33]. The general requirement for intro-
nic sequences, particularly those residing in BLG intron 1, for
detectable transcription in transgenic mice [15,16,34,35] argues
their involvement in preventing the localization of genes near
centromeric heterochromatin [36] or their barrier activity
against the propagation of heterochromatic domains [37].
In the absence of a functional enhancer(s) like those residing
in the BLG intragenic sequences, transgenes are frequently ex-
posed to the negative eﬀect of unstable integration sites [36].
We suggest that under those conditions, BLG-e1s eﬀect is re-
versed and its involvement in promoter acetylation is no longer
associated with improved expression. In this context, the best
example of a negative correlation between promoter activation
and gene expression in eukaryotes may be the case of mouse
mammary tumor virus promoter, in which transcription acti-
vation is blocked when histone acetylation is globally increased
under sodium butyrate or TSA treatment [6,38,39].
Indeed, acetylation has been associated with both the induc-
tion and silencing of promoter activity, and cooperation be-
tween promoter elements in mediating gene expression has
already been demonstrated with [40] or without [41] regard
to milk-protein gene expression. The novelty of BLG-e1s
‘‘ON’’ and ‘‘OFF’’ eﬀects on promoter activity lies in their un-
ique dependence on sequences residing 2.4 kb downstream in
the intragenic part of the BLG gene. This exclusive activity
may result from the dissimilarity between BLG-e1 and avail-
able mammalian genome sequences. The forthcoming comple-
tion of the bovine genomes sequencing will hopefully enable
the discovery and localization of additional genes regulated
by BLG-e1 and contribute to our understanding of its mecha-
nism of action.Acknowledgment: This study was supported by grants from the Chief
Scientist, Israeli Ministry of Agriculture.References
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